🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against superbug strains of the infection, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are on the rise around the world, with figures suggesting in excess of 82 million new cases each year. Notably increased rates are seen in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the context of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance found that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization represents a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

As per findings detailed in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This establishes an equal footing with the current standard treatment, which combines two antibiotics. The research involved hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the rights to make available and distribute the drug in many low-income and middle-income countries.

Medical professionals directly involved have shared positive views. Access to a single-dose, oral treatment of this kind is described as a "game-changer" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.